Study of KN046 With Chemotherapy in First Line Advanced NSCLC
Phase 2
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT04054531
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: KN019, 5mg/kgBiological: PlaceboBiological: KN019, 10 mg/kgCombination Product: Methotrexate
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 145
- Registration Number
- NCT04038970
- Locations
- 🇨🇳
Pingxiang people's hospital, PingXiang, Pingxiang, China
KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer
Phase 2
Completed
- Conditions
- Gastric/Gastroesophageal Junction Cancer
- Interventions
- Drug: KN026 10 mg/kg QWDrug: KN026 20 mg/kg Q2WDrug: KN026 30 mg/kg Q3W
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 45
- Registration Number
- NCT03925974
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 45
- Registration Number
- NCT03925870
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer
Phase 1
Completed
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Biological: KN046
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT03872791
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳LiaoCheng People's Hospital, Liaocheng, Shandong, China
🇨🇳Liaoning Cancer Hospital, Shenyang, Liaoning, China
KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 22
- Registration Number
- NCT03847168
- Locations
- 🇺🇸
Greenville Health System Center Institute, Greenville, South Carolina, United States
KN046 in Patients With Advanced Non-small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Stage IV Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT03838848
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
KN046 in Subjects With Advanced Solid Tumors and Lymphoma
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 139
- Registration Number
- NCT03733951
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 63
- Registration Number
- NCT03619681
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath